Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Not Applicable
Not yet recruiting
- Conditions
- Hepatopancreaticobiliary (HPB) MalignancyBladder CancerOvarian Cancer (OvCa)Kidney Cancers
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 148
- Registration Number
- NCT07050771
Ultrasound Evaluation for Baxter VASCU-GUARD Vascular Patches Post-Endarterectomy and Complications Assessment
Completed
- Conditions
- Carotid Endarterectomy (CEA) Surgical Patients
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 500
- Registration Number
- NCT07048067
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Stem Cells for Erectile Dysfunction Post RALP
Not Applicable
Not yet recruiting
- Conditions
- Erectile DysfunctionProstate Cancer
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT07048314
- Locations
- 🇺🇸
Houston Methodist, Houston, Texas, United States
Phase II Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT07042685
- Locations
- 🇺🇸
Houston Methodist Neal Cancer Center, Houston, Texas, United States
Surgical Site Infection Outcomes in Natural Orifice Intracorporeal Anastomosis and Extraction (NICE) Procedure - The NICE Trial
- Conditions
- DiverticulitisSurgical Site InfectionSurgical Site InfectionsColorectal SurgeryRobotic Surgical ProceduresClinical TrialsDiverticulitis, ColonicDiverticulitis ColonDiverticulitis; Perforation, Bowel
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 300
- Registration Number
- NCT06957236
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Dexamethasone for Ureteral STent Symptoms (DUSTS)
Phase 1
Not yet recruiting
- Conditions
- Ureteral Stent-Related Symptom
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 70
- Registration Number
- NCT06930690
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
Phase 2
Not yet recruiting
- Conditions
- Rejection Chronic Renal
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06751602
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 56
- Registration Number
- NCT06887218
- Locations
- 🇺🇸
Houston Methodist Neal Cancer Center, Houston, Texas, United States
Prehabilitation for Kidney Transplant Candidates
Not Applicable
Recruiting
- Conditions
- Kidney TransplantationFrailtyChronic Kidney Insufficiency
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06886256
- Locations
- 🇺🇸
Houston Methodist Hospital System, Houston, Texas, United States
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 33
- Registration Number
- NCT06833866
- Locations
- 🇺🇸
Houston Methodist., Houston, Texas, United States